Advertisement
-
1
Ray NF, Chan JK, Thamer M, et al: Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. .J Bone Miner Res 12::24. ,1997. .
-
2
Cummings SR, Black DM, Rubin SM: Lifetime risks of hip, Colles’, or vertebral fracture and coronary heart disease among white menopausal women. .Ann Intern Med 149::2445. ,1989. .
-
3
Gregg EW, Cauley JA, Seeley DG, et al: Physical activity and osteoporotic fracture risk in older women. .Ann Intern Med 129::81. ,1998. .
-
4
Siris ES, Miller PD, Barrett-Connor E, et al: Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women. .JAMA 286::2815. ,2001. .
-
5
Earnshaw SA, Cawte SA, Worley A, et al: Colles’ fracture of the wrist as an indicator of underlying osteoporosis in postmenopausal women: a prospective study of bone mineral density and bone turnover rate. .Osteoporosis Int 8::53. ,1998. .
-
6
Freedman KB, Kaplan FS, Bilker WB, et al: Treatment of osteoporosis: are physicians missing an opportunity?. J Bone Joint Surg Am 82::1063. ,2000. .
-
7
Cummings SR, Black DM, Nevitt MC, et al: Bone density at various sites for prediction of hip fractures. .Lancet 341::72. ,1993. .
-
8
Marshall D, Johnell O, Wedel H: Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. .BMJ 312::1254. ,1996. .
-
9
US Preventive Services Task Force: Screening for osteoporosis in postmenopausal women: recommendations and rationale. .Ann Intern Med 137::526. ,2002. .
-
10
Eastell R: Drug therapy: treatment of postmenopausal osteoporosis. .N Engl J Med 338::736. ,1998. .
-
11
Reid IR, Ames RW, Evans MC, et al: Long-term effects of calcium supplementation on bone loss and fractures in postmenopausal women: a randomized controlled trial. .Am J Med 98::331. ,1995. .
-
12
Hopper JL, Seeman E: The bone density of female twins discordant for tobacco use. .N Engl J Med 330::387. ,1994. .
-
13
Writing Group for the Women’s Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. .JAMA 288::321. ,2002. .
-
14
Black DM, Cummings SR, Karpf DB, et al: Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures: Fracture Intervention Trial Research Group. .Lancet 348::1535. ,1996. .
-
15
Cummings SR, Black DM, Thompson DE, et al: Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. .JAMA 280::2077. ,1998. .
-
16
Schnitzer T, Bone HG, Crepaldi SA, et al: Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. .Aging Clin Exp Res 12::1. ,2000. .
-
17
Ettinger B, Black DM, Mitlak BH, et al: Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. .JAMA 282::637. ,1999. .
-
18
Overgaard K, Hansen MA, Jensen SB, et al: Effect of calcitonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. .BMJ 305::556. ,1992. .
-
19
Neer RM, Arnaud CD, Zanchetta JR, et al: Effect of parathyroid hormone on fractures and bone mineral density in postmenopausal women with osteoporosis. .N Engl J Med 344::1434. ,2001. .
-
20
Ensrud KE, Black DM, Palermo L, et al: Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial. .Arch Intern Med 157::2617. ,1997. .
-
21
Cummings SR, Karpf DB, Harris F, et al: Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. .Am J Med 112::281. ,2002. .
-
22
Cummings SR, Palermo L, Browner W, et al: Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean: Fracture Intervention Trial Research Group. .JAMA 283::1318. ,2000. .
-
23
Sturtridge W, Lentle B, Hanley DA: The use of bone density measurement in the diagnosis and management of osteoporosis. .CMAJ 155::924. ,1996. .
-
24
Tonino RP, Meunier PJ, Emkey R, et al: Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women: Phase III Osteoporosis Treatment Study Group. .J Clin Endocrinol Metab 85::3109. ,2000. .
-
25
Stock JL, Bell NH, Chesnut CH, et al: Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women. .Am J Med 103::291. ,1997. .
Principles of Diagnosing and Managing Postmenopausal Osteoporosis for the Podiatric Physician
Search for other papers by Kelly A. McGarry in
Current site
Google Scholar
PubMed
Search for other papers by Michele G. Cyr in
Current site
Google Scholar
PubMed
Osteoporosis is an asymptomatic disease until a fracture occurs. The prevalence of osteoporosis will rise with the aging of the population. Recent advances have led to more efficacious treatment options. Targeted screening, educating patients about preventive strategies, and providing appropriate treatment for those at high risk will allow physicians to reduce the enormous morbidity and mortality associated with osteoporosis. (J Am Podiatr Med Assoc 94(2): 187-193, 2004)
